Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of second patient cohort Study is…
Categorie
2020
Data showed MaaT013 to be safe and effective in 29 heavily pre-treated and immunocompromised gastrointestinal (GI) acute Graft-versus-Host-Disease (aGvHD) patients…
December 7, 2020
— New investor Bpifrance leads Series B extension through the PSIM fund it manages on behalf of the French State…
December 1, 2020
Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe, demonstrating positive impact Lyon, France,…
November 25, 2020
MaaT033 is an oral formulation of MaaT Pharma’s full–ecosystem biotherapeutic characterized by high microbial diversity and richness Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy [divider line_type=”No Line” custom_height=”30″]Lyon, France, November…
November 12, 2020
— Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013, MaaT Pharma’s full-ecosystem microbiota biotherapeutic,…
August 31, 2020
— Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will…
August 28, 2020
New collection campaign to support future clinical development of microbiome biotherapeutic product portfolio and to supply the French compassionate use…
August 20, 2020
Lyon, France, July 16, 2020 – MaaT Pharma announced today the appointment of Claude Bertrand, PharmD, PhD, as an independent…
July 16, 2020
—MaaT Pharma renforce son équipe de direction en ajoutant une expertise en termes de développement commercial stratégique et de marketing…
May 28, 2020
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.